论文部分内容阅读
目的:探讨孟鲁司特钠联合布地奈德治疗儿童咳嗽变异性哮喘(CVA)的临床疗效,并分析其炎症因子的影响,为临床提供参考依据。方法:选取2011年10月~2013年10月本院住院治疗的90例CVA患儿,根据用药方法不同随机分为A组和B组各45例。A组给予孟鲁司特钠联合布地奈德治疗;B组给予布地奈德治疗,疗程均为3个月。主要观察两组患者临床疗效、主要症状或体征改善时间,随访12个月观察复发率。检测治疗后血清中TNF-α、IL-8及Ig E水平。结果:A组总有效率(97.78%)高于B组(82.22%),差异具有统计学意义(P<0.05);A组复发率(4.44%)低于B组(15.56%),两组比较,差异具有统计学意义(P<0.05);A组患儿治疗后咳嗽评分[(0.58±0.22)分]、低于B组[(1.03±0.27)分],两组比较,差异具有统计学意义(P<0.05)。A组患儿咳嗽消失和喘憋消失时间分别为(7.19±0.47)天和(8.04±0.73)天,均少于B组,,两组比较,差异具有统计学意义(P<0.05)。A组患儿治疗后TNF-α[(0.77±0.12)ng/m L]、IL-8[(10.92±0.83)pg/ml]和Ig E[(159.31±11.48)IU/ml]均低于B组,两组比较,差异具有统计学意义(P<0.05)。结论:孟鲁司特钠联合布地奈德治疗儿童CVA能够提高临床治疗效果,患儿的症状或体征得到显著改善,缩短患儿症状或体征改善时间,并可降低患儿复发率和炎症因子水平。
Objective: To investigate the clinical efficacy of montelukast combined with budesonide in the treatment of children with cough variant asthma (CVA), and to analyze the impact of its inflammatory cytokines for clinical reference. Methods: Ninety children with CVA hospitalized in our hospital from October 2011 to October 2013 were randomly divided into group A and group B (n = 45) according to different methods of treatment. Group A received montelukast combined with budesonide, while group B received budesonide for 3 months. Mainly observe the clinical efficacy of two groups of patients, the main symptoms or signs of improvement time, followed up for 12 months to observe the recurrence rate. Serum levels of TNF-α, IL-8 and Ig E were detected after treatment. Results: The total effective rate in group A (97.78%) was higher than that in group B (82.22%), the difference was statistically significant (P <0.05). The recurrence rate in group A was lower than that in group B (15.46% (0.58 ± 0.22), lower than that in group B [(1.03 ± 0.27) minutes], the difference between the two groups was statistically significant (P0.05) .After treatment, the score of cough in group A was statistically significant Significance (P <0.05). The duration of cough disappearance and wheezing disappeared in group A were (7.19 ± 0.47) days and (8.04 ± 0.73) days, respectively, which were less than those in group B. The difference between the two groups was statistically significant (P <0.05). The levels of TNF-α [(0.77 ± 0.12) ng / m L], IL-8 [(10.92 ± 0.83) pg / ml] and Ig E [(159.31 ± 11.48) IU / ml] Group B, the difference between the two groups was statistically significant (P <0.05). Conclusion: Montelukast combined with budesonide in children with CVA can improve the clinical effect of treatment, the symptoms or signs of children have been significantly improved, shorten the children’s symptoms or signs of improvement, and can reduce the children’s relapse rate and the level of inflammatory cytokines .